Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.

Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA.

Clin Cancer Res. 2006 Aug 1;12(15):4545-52.

2.

Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.

Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA.

Expert Rev Mol Diagn. 2005 Sep;5(5):701-13. Review.

PMID:
16149873
4.

Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer.

Bustin SA, Mueller R.

Mol Aspects Med. 2006 Apr-Jun;27(2-3):192-223. Epub 2006 Jan 30. Review.

PMID:
16445974
5.

Guanylyl cyclase C as a biomarker in colorectal cancer.

Hyslop T, Waldman SA.

Biomark Med. 2013 Feb;7(1):159-67. doi: 10.2217/bmm.12.90. Review.

6.

Prognostic relevance of occult tumour cells in lymph nodes in colorectal cancer.

Doekhie FS, Kuppen PJ, Peeters KC, Mesker WE, van Soest RA, Morreau H, van de Velde CJ, Tanke HJ, Tollenaar RA.

Eur J Surg Oncol. 2006 Apr;32(3):253-8. Epub 2006 Jan 18. Review.

PMID:
16412600
7.

Molecular detection of minimal residual disease in colorectal and breast cancer.

Liefers GJ, Tollenaar RA, Cleton-Jansen AM.

Histopathology. 1999 May;34(5):385-90. Review.

PMID:
10231411
8.

Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis.

Bustin SA, Mueller R.

Clin Sci (Lond). 2005 Oct;109(4):365-79. Review.

PMID:
16171460
9.

Can colorectal cancer be prevented or treated by oral hormone replacement therapy?

Li P, Lin JE, Schulz S, Pitari GM, Waldman SA.

Curr Mol Pharmacol. 2009 Nov;2(3):285-92. Review.

10.

Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Lin JE, Li P, Pitari GM, Schulz S, Waldman SA.

Future Oncol. 2009 May;5(4):509-22. doi: 10.2217/fon.09.14. Review.

11.

Quantitative RT-PCR: pitfalls and potential.

Freeman WM, Walker SJ, Vrana KE.

Biotechniques. 1999 Jan;26(1):112-22, 124-5. Review.

PMID:
9894600
12.

GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Li P, Lin JE, Marszlowicz GP, Valentino MA, Chang C, Schulz S, Pitari GM, Waldman SA.

Drug News Perspect. 2009 Jul-Aug;22(6):313-8. doi: 10.1358/dnp.2009.22.6.1395254. Review.

13.

Molecular staging individualizing cancer management.

Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA.

J Surg Oncol. 2012 Apr 1;105(5):468-74. doi: 10.1002/jso.21858. Review.

14.

Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.

Li P, Waldman SA.

Cancer Biol Ther. 2010 Aug 1;10(3):211-8. Epub 2010 Aug 11. Review.

15.

GUCY2C molecular staging personalizes colorectal cancer patient management.

Gong JP, Schulz S, Hyslop T, Waldman SA.

Biomark Med. 2012 Jun;6(3):339-48. doi: 10.2217/bmm.12.24. Review.

16.

Quantitative real-time PCR: a powerful ally in cancer research.

Mocellin S, Rossi CR, Pilati P, Nitti D, Marincola FM.

Trends Mol Med. 2003 May;9(5):189-95. Review.

PMID:
12763523
17.

Reverse transcription-polymerase chain reaction quantitation of steroid receptor mRNA levels.

Wang HB.

J Lab Clin Med. 2001 Jun;137(6):379-80. Review. No abstract available.

PMID:
11385357
18.

Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.

Waldman SA, Fortina P, Surrey S, Hyslop T, Kricka LJ, Graves DJ.

Future Oncol. 2006 Dec;2(6):705-16. Review.

PMID:
17155897

Supplemental Content

Support Center